Proven Intelligence in Vector Analytics.
The integrity of the analytical data package is the foundation for any successful IND submission for a next-generation therapeutic. Inconsistencies or gaps in vector characterization data identified late in development can compromise program timelines. A proactive analytical strategy, implemented from the earliest stages, is the most direct path to a defensible regulatory filing.
A robust program begins with the genetic source material. The complete and accurate sequence of the AAV cis-plasmid must be confirmed before committing to vector production. Leveraging rapid, high-fidelity NGS methods for full-plasmid validation provides absolute certainty in the vector’s genetic blueprint (PMID: 30051733). This initial quality control step eliminates the risk of manufacturing a vector with unintended sequence variants, a flaw that would invalidate all subsequent data.
For programs utilizing novel or engineered capsids, such as modified AAV9 or other serotypes, the analytical burden is higher. Characterization must rigorously document how specific modifications alter the vector’s biological properties. This includes assessing potential changes to tissue tropism and mapping neutralizing epitopes to understand the vector’s immunogenic profile (PMID: 30089698). This level of detail provides a clear, data-driven rationale for the vector’s design and its anticipated performance in preclinical models.
These discrete analytical activities must be integrated into a single, coherent data narrative that supports global regulatory filings. Our teams operate across a >100,000 sq ft facilityto generate consistent, GxP-compliant data suitable for both FDA and MHRA submissions. This unified approach ensures that all characterization, potency, and purity data aligns with the expectations of international health authorities.
Ultimately, this rigorous, front-loaded analytical work directly enables predictable preclinical outcomes. By building a foundation of unimpeachable data on vector identity, purity, and function, sponsors can proceed into IND-enabling toxicology studies with confidence. This integration of analytics and preclinical strategy is central to achieving 18-24 month IND timelines, a track record established by our core scientific leadership prior to the formal launch of Franklin Biolabs in 2024. Our comprehensive Vector | CMC | Analytics Services provide the framework for this accelerated path.
